245 related articles for article (PubMed ID: 23416698)
1. MiR-106a is an independent prognostic marker in patients with glioblastoma.
Zhao S; Yang G; Mu Y; Han D; Shi C; Chen X; Deng Y; Zhang D; Wang L; Liu Y; Hou X; Wang C; Wu J; Liu H; Wang L; Zhang G; Qi J; Fang X; Shi C; Ai J
Neuro Oncol; 2013 Jun; 15(6):707-17. PubMed ID: 23416698
[TBL] [Abstract][Full Text] [Related]
2. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
3. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.
Chen J; Yang L; Wang X
Cancer Biomark; 2017 Dec; 20(4):521-526. PubMed ID: 28946553
[TBL] [Abstract][Full Text] [Related]
4. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
[TBL] [Abstract][Full Text] [Related]
5. Similarly up-regulated microRNA-106a in matched formalin-fixed paraffin-embedded and fresh frozen samples and the dynamic changes during gastric carcinogenesis and development.
Zhu M; Zhang N; He S
Pathol Res Pract; 2014 Dec; 210(12):909-15. PubMed ID: 25115709
[TBL] [Abstract][Full Text] [Related]
6. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
7. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.
Manterola L; Guruceaga E; Gállego Pérez-Larraya J; González-Huarriz M; Jauregui P; Tejada S; Diez-Valle R; Segura V; Samprón N; Barrena C; Ruiz I; Agirre A; Ayuso A; Rodríguez J; González A; Xipell E; Matheu A; López de Munain A; Tuñón T; Zazpe I; García-Foncillas J; Paris S; Delattre JY; Alonso MM
Neuro Oncol; 2014 Apr; 16(4):520-7. PubMed ID: 24435880
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-106a-5p facilitates human glioblastoma cell proliferation and invasion by targeting adenomatosis polyposis coli protein.
Li D; Wang Z; Chen Z; Lin L; Wang Y; Sailike D; Luo K; Du G; Xiang X; Jiafu GD
Biochem Biophys Res Commun; 2016 Dec; 481(3-4):245-250. PubMed ID: 27815074
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.
Chen SM; Chen HC; Chen SJ; Huang CY; Chen PY; Wu TW; Feng LY; Tsai HC; Lui TN; Hsueh C; Wei KC
World J Surg Oncol; 2013 Apr; 11():87. PubMed ID: 23594394
[TBL] [Abstract][Full Text] [Related]
10. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
[TBL] [Abstract][Full Text] [Related]
11. miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma.
Shi Y; Chen C; Yu SZ; Liu Q; Rao J; Zhang HR; Xiao HL; Fu TW; Long H; He ZC; Zhou K; Yao XH; Cui YH; Zhang X; Ping YF; Bian XW
Clin Cancer Res; 2015 Sep; 21(17):4004-13. PubMed ID: 26023083
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme.
Barbagallo D; Condorelli A; Ragusa M; Salito L; Sammito M; Banelli B; Caltabiano R; Barbagallo G; Zappalà A; Battaglia R; Cirnigliaro M; Lanzafame S; Vasquez E; Parenti R; Cicirata F; Di Pietro C; Romani M; Purrello M
Oncotarget; 2016 Jan; 7(4):4746-59. PubMed ID: 26683098
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform.
Swellam M; Ezz El Arab L; Al-Posttany AS; B Said S
J Neurooncol; 2019 Sep; 144(3):545-551. PubMed ID: 31422498
[TBL] [Abstract][Full Text] [Related]
14. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
Yerukala Sathipati S; Huang HL; Ho SY
BMC Genomics; 2016 Dec; 17(Suppl 13):1022. PubMed ID: 28155650
[TBL] [Abstract][Full Text] [Related]
15. Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.
Ilhan-Mutlu A; Wöhrer A; Berghoff AS; Widhalm G; Marosi C; Wagner L; Preusser M
J Neurooncol; 2013 May; 112(3):347-54. PubMed ID: 23420397
[TBL] [Abstract][Full Text] [Related]
16. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
17. Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM.
Dai DW; Lu Q; Wang LX; Zhao WY; Cao YQ; Li YN; Han GS; Liu JM; Yue ZJ
BMC Cancer; 2013 Oct; 13():478. PubMed ID: 24124917
[TBL] [Abstract][Full Text] [Related]
18. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
[TBL] [Abstract][Full Text] [Related]
19. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
20. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
